Citius Pharmaceuticals (CTXR)
(Delayed Data from NSDQ)
$0.47 USD
-0.03 (-6.49%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $0.46 -0.01 (-1.73%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CTXR 0.47 -0.03(-6.49%)
Will CTXR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CTXR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTXR
After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)
CTXR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CTXR
Biotech Alert: Searches spiking for these stocks today
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR? (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton
Earnings week ahead: Zoom, Lowe's, Target, Baidu, XPeng, Zim Integrated and more